DISCLAIMER: GOLDINVESTMENTCOMPANIES.COM IS AN AFFILIATED PARTNER FOR GOLDCO PRECIOUS METALS, AUGUSTA PRECIOUS METALS, AND BIRCH GOLD GROUP, PROMOTING THEIR GOLD IRA, GOLD 401K TRANSFER AND BITCOIN IRA SERVICES AND PRODUCTS.
Description: Cleo Diagnostics (ASX:COV) CEO Richard Allman discusses how the company’s patented biomarker technology will help increase the survival rate for women diagnosed with Stage 1 ovarian cancer through a simple blood test.
00:00 Introduction
00:37 Overview of the company and value proposition
02:46 Overview of the ovarian cancer screening technology and why is it important
04:16 What makes the Cleo ovarian cancer screening technology unique?
05:46 CLEO’s ovarian cancer detection technology’s path to commercialization
09:20 Upcoming catalysts for the company
15:17 What makes Cleo a compelling investment opportunity?
#medicaldevice #lifescience #investing
________________________________________________________________
Investing News Network (INN)
Find out more about Cleo Diagnostics: https://bit.ly/3IVm4rn
Browse our 2023 outlook reports:
http://bit.ly/3JHyR1M
Follow us Facebook:
https://www.facebook.com/investing.news.your.trusted.source
Follow us on Twitter:
@INN_Resource
________________________________________________________________
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
